215 related articles for article (PubMed ID: 24220559)
21. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
22. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Micallef IN; Maurer MJ; Wiseman GA; Nikcevich DA; Kurtin PJ; Cannon MW; Perez DG; Soori GS; Link BK; Habermann TM; Witzig TE
Blood; 2011 Oct; 118(15):4053-61. PubMed ID: 21673350
[TBL] [Abstract][Full Text] [Related]
23. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
24. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
Chang JE; Seo S; Kim KM; Werndli JE; Bottner WA; Rodrigues GA; Sanchez FA; Saphner TJ; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):379-84. PubMed ID: 21030351
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
26. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.
Chaiwatanatorn K; Stamaratis G; Opeskin K; Firkin F; Nandurkar H
Leuk Lymphoma; 2009 Oct; 50(10):1666-75. PubMed ID: 19757311
[TBL] [Abstract][Full Text] [Related]
27. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl A; Cunningham D; Counsell N; Hawkes EA; Qian W; Smith P; Chadwick N; Lawrie A; Mouncey P; Jack A; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Rosenwald A; Ott G; Horn H; Ziepert M; Pfreundschuh M; Linch D
Ann Oncol; 2017 Jul; 28(7):1540-1546. PubMed ID: 28398499
[TBL] [Abstract][Full Text] [Related]
28. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K; Yamaguchi M; Atsuta Y; Matsue K; Sato K; Kusumoto S; Nagai H; Takizawa J; Fukuhara N; Nagafuji K; Miyazaki K; Ohtsuka E; Okamoto M; Sugita Y; Uchida T; Kayukawa S; Wake A; Ennishi D; Kondo Y; Izumi T; Kin Y; Tsukasaki K; Hashimoto D; Yuge M; Yanagisawa A; Kuwatsuka Y; Shimada S; Masaki Y; Niitsu N; Kiyoi H; Suzuki R; Tokunaga T; Nakamura S; Kinoshita T
Lancet Oncol; 2020 Apr; 21(4):593-602. PubMed ID: 32171071
[TBL] [Abstract][Full Text] [Related]
29. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
30. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.
Hasselblom S; Stenson M; Werlenius O; Sender M; Lewerin C; Hansson U; Nilsson-Ehle H; Andersson PO
Leuk Lymphoma; 2012 Mar; 53(3):394-9. PubMed ID: 21864039
[TBL] [Abstract][Full Text] [Related]
31. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
32. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
Witzig TE; Hong F; Micallef IN; Gascoyne RD; Dogan A; Wagner H; Kahl BS; Advani RH; Horning SJ
Br J Haematol; 2015 Sep; 170(5):679-86. PubMed ID: 25974212
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T; Tsurumi H; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Kasahara S; Goto H; Fukuno K; Yamada T; Sawada M; Yasuda I; Katsumura N; Takahashi T; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2010 Jan; 136(1):65-70. PubMed ID: 19590893
[TBL] [Abstract][Full Text] [Related]
35. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.
Xu PP; Fu D; Li JY; Hu JD; Wang X; Zhou JF; Yu H; Zhao X; Huang YH; Jiang L; Liu F; Su LP; Chen ZW; Zeng QS; Chen JP; Fang MY; Ma J; Liu T; Song YP; Yu K; Li Y; Qiu LG; Chen XQ; Gu J; Yan JS; Hou M; Huang HY; Wang L; Cheng S; Shen Y; Xiong H; Chen SJ; Zhao WL
Lancet Haematol; 2019 Jun; 6(6):e328-e337. PubMed ID: 31126528
[TBL] [Abstract][Full Text] [Related]
36. Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid.
Jonak C; Troch M; Müllauer L; Niederle B; Hoffmann M; Raderer M
Thyroid; 2010 Apr; 20(4):425-7. PubMed ID: 20210673
[TBL] [Abstract][Full Text] [Related]
37. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
Barton S; Hawkes EA; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Attygalle A; Horwich A; Potter M; Ethell M; Dearden C; Gleeson M; Chau I
Eur J Haematol; 2015 Mar; 94(3):219-26. PubMed ID: 25039915
[TBL] [Abstract][Full Text] [Related]
38. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
[TBL] [Abstract][Full Text] [Related]
39. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
40. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
